Next Article in Journal
Emergency Management of Major Bleeding in a Case of Maxillofacial Trauma and Anticoagulation: Utility of Prothrombin Complex Concentrates in the Shock Room
Previous Article in Journal
Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma
 
 
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Interferon α Therapy in Patients with Chronic Hepatitis C Infection: Quality of Life and Depression

by
Ciro Conversano
1,
Claudia Carmassi
1,*,
Marina Carlini
1,
Giulia Casu
2,
Paola Gremigni
2 and
Liliana Dell’Osso
1
1
Section of Psychiatry, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56100 Pisa, Italy
2
Department of Psychology, University of Bologna, 40126 Bologna, Italy
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2015, 7(1), 5632; https://doi.org/10.4081/hr.2015.5632
Submission received: 11 September 2014 / Revised: 6 January 2015 / Accepted: 23 January 2015 / Published: 3 March 2015

Abstract

Health-related quality of life was examined in 49 patients with hepatitis C virus with no psychiatric history who received interferon (IFN)-α treatment. Quality of life was assessed at baseline, at 3-time points during IFN-α therapy and at 1-6 month follow-up, using SF-36. Hepatitis C virus patients showed poorer physical functioning and better social and mental functioning than a normal population. Significant decreases from baseline SF-36 scores were observed at an early phase of treatment. Six patients developed major depression during IFN-α treatment. At baseline, they had reported more bodily pain than patients who did not develop depression during treatment. Planned contrasts revealed that worsening in some dimensions of quality of life at 2 months was greater in depressed than in non-depressed patients. Results suggest that depressive symptoms should be accurately monitored during IFN-α therapy even in patients with no psychiatric history, especially if they present with bodily pain.
Keywords: depression; HCV; interferon; quality of life depression; HCV; interferon; quality of life

Share and Cite

MDPI and ACS Style

Conversano, C.; Carmassi, C.; Carlini, M.; Casu, G.; Gremigni, P.; Dell’Osso, L. Interferon α Therapy in Patients with Chronic Hepatitis C Infection: Quality of Life and Depression. Hematol. Rep. 2015, 7, 5632. https://doi.org/10.4081/hr.2015.5632

AMA Style

Conversano C, Carmassi C, Carlini M, Casu G, Gremigni P, Dell’Osso L. Interferon α Therapy in Patients with Chronic Hepatitis C Infection: Quality of Life and Depression. Hematology Reports. 2015; 7(1):5632. https://doi.org/10.4081/hr.2015.5632

Chicago/Turabian Style

Conversano, Ciro, Claudia Carmassi, Marina Carlini, Giulia Casu, Paola Gremigni, and Liliana Dell’Osso. 2015. "Interferon α Therapy in Patients with Chronic Hepatitis C Infection: Quality of Life and Depression" Hematology Reports 7, no. 1: 5632. https://doi.org/10.4081/hr.2015.5632

APA Style

Conversano, C., Carmassi, C., Carlini, M., Casu, G., Gremigni, P., & Dell’Osso, L. (2015). Interferon α Therapy in Patients with Chronic Hepatitis C Infection: Quality of Life and Depression. Hematology Reports, 7(1), 5632. https://doi.org/10.4081/hr.2015.5632

Article Metrics

Back to TopTop